(Q42605936)

English

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).

scientific article published on January 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC). (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

author name string

Rosing H

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

ten Bokkel Huinink WW

2

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

van Gijn R

3

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Rombouts RF

4

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Bult A

5

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Beijnen JH

6

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

publication date

1 January 1999

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

European Journal of Drug Metabolism and Pharmacokinetics

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

69-77

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

New data on the pharmacokinetics of adriamycin and its major metabolite, adriamycinol

1 reference

https://api.crossref.org/works/10.1007%2FBF03190013

21 January 2018

Sequential chemotherapy in good-prognosis patients with small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FBF03190013

21 January 2018

The hydrolysis activation of the doxorubicin cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bioequivalence. An updated reappraisal addressed to applications of interchangeable multi-source pharmaceutical products.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical trial and pharmacokinetics of weekly ICRF-187 (NSC 169780) infusion in patients with solid tumors

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase II trial of cardioprotection with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardioxane--ICRF-187 towards anticancer drug specificity through selective toxicity reduction

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardioprotection with ICRF-187 (Cardioxane) in patients with advanced breast cancer having cardiac risk factors for doxorubicin cardiotoxicity, treated with the FDC regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Statistical aspects of bioequivalence--a review

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cross-over study of pharmacokinetics and haematological toxicity of 4'-epi-doxorubicin and doxorubicin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of anthracyclines

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of methods and criteria for the evaluation of bioequivalence studies

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of (+)-1,2-di(3,5-dioxopiperazin-1-yl)propane intravenous infusions in adult cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HPLC determination of doxorubicin, doxorubicinol and four aglycone metabolites in plasma of AIDS patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/10412894

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF03190013

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42605936&oldid=2205532383"